Earnings Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:

	Years ended December 31,
(in millions, except per share data)	2019		2018		2017
Basic EPS
Net earnings	$	7,882	$	5,687	$	5,309
Earnings allocated to participating securities	40		30		26
Earnings available to common shareholders	$	7,842	$	5,657	$	5,283
Weighted-average basic shares outstanding	1,481		1,541		1,596
Basic earnings per share	$	5.30	$	3.67	$	3.31
Diluted EPS
Net earnings	$	7,882	$	5,687	$	5,309
Earnings allocated to participating securities	40		30		26
Earnings available to common shareholders	$	7,842	$	5,657	$	5,283
Weighted-average shares of common stock outstanding	1,481		1,541		1,596
Effect of dilutive securities	3		5		7
Weighted-average diluted shares outstanding	1,484		1,546		1,603
Diluted earnings per share	$	5.28	$	3.66	$	3.30

Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.